Is Glargine the Same as Lantus? Brands and Cost

Insulin glargine is the active ingredient in Lantus, so in a pharmacological sense they are the same molecule. Lantus is simply the original brand name that Sanofi gave to its insulin glargine product when it came to market. Today, several other brands sell insulin glargine under different names and at different prices, which is where the practical confusion begins.

What the Different Brand Names Actually Mean

Lantus was the first commercially available insulin glargine product, and for years it was the only option. After patents began expiring, other manufacturers developed their own versions. The main insulin glargine products you’ll encounter in U.S. pharmacies today include Lantus (Sanofi), Basaglar (Eli Lilly), Semglee (Viatris, formerly Mylan), and Rezvoglar (Eli Lilly). All contain insulin glargine at 100 units per milliliter and are designed to do the same job: provide a steady baseline of insulin over roughly 24 hours.

Toujeo, also made by Sanofi, contains the same glargine molecule but at a higher concentration of 300 units per milliliter. That concentration difference changes how the insulin behaves once it’s under the skin, so Toujeo isn’t treated as interchangeable with Lantus despite sharing the same active ingredient.

These products are not traditional generics. Insulin is a biologic, meaning it’s produced by living cells rather than synthesized through chemical reactions. Because of that, follow-on versions are called “biosimilars” rather than generics. A biosimilar must demonstrate that it is highly similar to the reference product and that there are no clinically meaningful differences in safety or effectiveness.

Biosimilar Versus Interchangeable

Not all glargine biosimilars carry the same regulatory designation, and the distinction matters at the pharmacy counter. A product labeled simply as a “biosimilar” has been shown to work essentially the same as the reference drug, but your pharmacist can’t automatically swap it in place of Lantus without your prescriber’s involvement, depending on state law. An “interchangeable” biosimilar, on the other hand, has met a higher regulatory bar. Your pharmacist can substitute it for Lantus much like they would swap a brand-name pill for a generic, again subject to state-level rules.

Insulin glargine-yfgn (the version sold as Semglee) was the first biosimilar insulin to earn interchangeable status with Lantus.¹ Rezvoglar later became another glargine product designated as interchangeable.² Basaglar is approved as a biosimilar but has not received the interchangeable designation. In clinical practice, the difference between a biosimilar and an interchangeable product is mostly administrative rather than medical; the clinical data for Basaglar are strong, but the pharmacy substitution pathway is a bit more cumbersome in many states.

Clinical Evidence That Biosimilars Match Lantus

A reasonable concern when switching from Lantus to a biosimilar is whether blood sugar control will stay the same. The short answer from clinical trials is yes. In the ELEMENT-2 study, patients with type 2 diabetes treated with Basaglar showed virtually identical reductions in A1C compared to those on Lantus, and the proportion of patients reaching an A1C below 7% was similar in both groups regardless of whether patients were younger or older than 65.³ Rates of hypoglycemia, including nighttime low blood sugar episodes, were also comparable between the two.

The ELEMENT-5 trial extended these findings to patients who were either new to insulin or already using it. At 24 weeks, Basaglar proved noninferior to Lantus for A1C change, and no meaningful differences emerged in insulin dose requirements, hypoglycemia rates, adverse events, or weight gain.⁴

Pharmacokinetic studies have also been conducted to confirm that biosimilar glargine behaves the same way in the body as Lantus. One randomized crossover clamp study in healthy volunteers compared the absorption and blood-sugar-lowering profiles of a biosimilar glargine against Lantus and found the two were similar for both the parent insulin and its primary active metabolite.⁵

What Happens When Real Patients Switch

Clinical trials are controlled environments, so real-world data from actual pharmacy switches adds a useful layer of reassurance. A study from a large public healthcare system in Saudi Arabia that moved patients from Lantus to Basaglar found no significant change in A1C levels after the switch.⁶ A U.S. retrospective study looking at patients converted from Lantus to Basaglar reached a similar conclusion: there was no significant difference in daily insulin dose or A1C at three, six, or twelve months after the switch.⁷ These findings suggest that for most patients, switching between glargine products is straightforward and doesn’t require dose adjustments.

That said, any insulin switch warrants closer monitoring for the first few weeks. Individual responses can vary for reasons unrelated to the insulin itself, including changes in diet, activity, or injection technique. Your prescriber will typically ask you to check blood sugars more frequently during the transition period.

Immunogenicity Across Brands

One concern specific to biologic medicines is whether a biosimilar might trigger a different immune response than the original. If your body develops antibodies against insulin, those antibodies can theoretically reduce the drug’s effectiveness or cause reactions. The evidence across multiple studies shows that glargine biosimilars and Lantus produce comparable immune responses.

In a 24-week study of Chinese patients with type 1 or type 2 diabetes, the proportion of patients developing detectable anti-insulin antibodies was similar between Basaglar and Lantus, and antibody levels remained low in both groups.⁸ The INSTRIDE trials, which evaluated the Mylan/Viatris biosimilar (the molecule behind Semglee), also found comparable rates of total and cross-reactive antibodies between the biosimilar and Lantus.⁹ A separate trial of another biosimilar called Ezelin showed that only about 1.7% of biosimilar patients and 1.6% of Lantus patients experienced a change in insulin antibodies from baseline.¹⁰

The bottom line on immunogenicity is that switching glargine brands doesn’t appear to introduce new immune risks. This has been one of the more thoroughly studied aspects of insulin biosimilars precisely because it was a key regulatory concern.

How Toujeo Fits In

Toujeo uses the same glargine molecule as Lantus but packs it at three times the concentration. That changes the drug’s behavior under the skin in a clinically relevant way. Because the more concentrated solution forms a smaller depot after injection, it’s absorbed more slowly and evenly. A review of the EDITION clinical trial program found that Toujeo’s glucose-lowering effect was more constant over 24 hours and lasted roughly five hours longer than standard glargine at 100 units per milliliter.¹¹

This makes Toujeo a distinct product in practice, even though the molecule is identical. You can’t substitute Toujeo for Lantus unit-for-unit; the dose often needs adjustment when transitioning between the two concentrations. Toujeo is typically positioned for patients who need higher doses or who experience overnight blood sugar variability on standard glargine. It is generally more expensive than Lantus and its biosimilars, and no interchangeable biosimilar of Toujeo exists yet.

Cost Differences and What Drives Them

Cost is frequently the reason patients and insurers care about the distinction between glargine brands. Lantus has been one of the most expensive insulin products on the market, and the arrival of biosimilars introduced price competition. The list price of insulin glargine-yfgn (Semglee) was set meaningfully lower than Lantus’s, and that competition has pushed down pricing across the category.¹ Basaglar is also generally priced below Lantus, and some manufacturers have released unbranded or “authorized generic” versions at even lower list prices.

Your actual out-of-pocket cost depends heavily on your insurance plan’s formulary. Some plans have negotiated deep rebates on Lantus and placed it on a preferred tier, making it cheaper for the patient than a biosimilar that has a lower list price but no rebate deal. Other plans have moved to biosimilars as their preferred glargine and charge more for Lantus. Checking with your insurance or pharmacy benefits manager before assuming a biosimilar will save you money is worth the few minutes it takes.

For Medicare beneficiaries specifically, the Inflation Reduction Act introduced a $35-per-month out-of-pocket cap on insulin. A study of Medicare Part D data found that after the policy took effect, the average 30-day cost of insulin to patients dropped by about 21%, falling from roughly $23 to about $18 per fill.¹² The cap flattened the wild month-to-month variation patients used to experience when their deductible phase kicked in. This policy applies to all covered insulin products, so for Medicare enrollees the brand-versus-biosimilar cost gap may matter less than it once did.

Why It Took So Long for Biosimilars to Arrive

Lantus was approved in the early 2000s, yet the first biosimilar didn’t reach U.S. pharmacies until late 2016. Part of the delay was regulatory: the pathway for approving biosimilar insulins took years to establish. But patent litigation played a major role as well. Sanofi held patents not just on the insulin glargine formulation but also on the SoloStar pen device used to deliver it. When Eli Lilly sought approval for Basaglar, Sanofi sued for patent infringement. The resulting litigation delayed Basaglar’s launch, and Sanofi later pursued similar lawsuits against Mylan and Merck. These were eventually settled, but the delays meant Sanofi collected billions in additional U.S. revenue on Lantus during the years competition was kept at bay.¹³

This dynamic is not unique to insulin glargine. The global insulin supply is dominated by a small number of manufacturers, and patent strategies have historically limited competition across many insulin types. The emergence of biosimilar glargine products represents one of the more significant cracks in that concentrated market.

Pharmacy Substitution Varies by State

Even when a glargine biosimilar carries the interchangeable designation, whether your pharmacist can automatically swap it for Lantus depends on where you live. State laws govern biosimilar substitution, and they vary considerably. Some states allow pharmacists to substitute an interchangeable biosimilar without contacting the prescriber, much like they would with a traditional generic. Others require the pharmacist to notify the prescriber, wait for a response, or document the switch in specific ways. A recent study characterized these state-level requirements and found that more restrictive substitution laws were associated with slower uptake of interchangeable insulin biosimilars.¹⁴

If your prescriber writes “Lantus” on the prescription, what actually gets dispensed may depend on your state’s laws, your insurance formulary, and your pharmacy’s stock. In states with permissive substitution laws and insurance plans that prefer biosimilars, you could walk out with Semglee or Rezvoglar without anyone specifically requesting it. In more restrictive states, the prescription may need to be rewritten. If brand matters to you in either direction, it’s worth explicitly discussing it with your prescriber and pharmacist.

Pen Devices and the Practical Side of Switching

One thing that does change between brands is the injection pen. Lantus uses Sanofi’s SoloStar pen, while Basaglar and Semglee use their own designs. The pens differ in appearance, dose-dialing mechanism, and the force required to push the plunger. A laboratory comparison found that SoloStar required consistently lower injection force than several competing pen devices.¹⁵ However, a separate usability survey comparing the Lantus pen to the pen used with the Merck biosimilar (now Rezvoglar) found that a majority of both patients and certified diabetes educators actually preferred the competing pen for overall appearance and function.¹⁶

The pen differences are unlikely to affect blood sugar control, but they can affect your daily experience with the injection. If you’ve been using one pen for years and switch brands, you’ll want to take a moment to familiarize yourself with the new device’s dose counter, button feel, and needle attachment. Pharmacists and diabetes educators can walk you through the differences. None of the currently available glargine pens are compatible with each other’s cartridges, so you can’t simply swap the insulin into a pen you already own.

Injection-Site Comfort and Formulation Differences

While the active molecule is the same, the inactive ingredients in each brand’s formulation differ slightly. These excipients, including preservatives, buffering agents, and pH adjusters, can influence injection-site comfort. The pH of an insulin formulation relative to the body’s tissue pH is one factor that affects whether an injection stings. Formulations with a pH further from the body’s natural level tend to activate pain receptors at the injection site more readily.¹⁷

In practice, most patients don’t notice a difference in injection-site comfort between glargine brands. But if you experience more stinging or local irritation after switching, the formulation differences are a plausible explanation. This isn’t a sign the insulin is working differently; it’s a surface-level sensation related to the non-active ingredients. Rotating injection sites and ensuring the insulin is at room temperature before injecting can help minimize discomfort regardless of brand.